Investors sold shares of Thermo Fisher Scientific Inc (NYSE:TMO) on strength during trading hours on Tuesday. $50.53 million flowed into the stock on the tick-up and $69.03 million flowed out of the stock on the tick-down, for a money net flow of $18.50 million out of the stock. Of all stocks tracked, Thermo Fisher Scientific had the 22nd highest net out-flow for the day. Thermo Fisher Scientific traded up $0.02 for the day and closed at $186.02

Several analysts recently commented on the stock. Cowen and Company reiterated a “buy” rating and issued a $200.00 price target on shares of Thermo Fisher Scientific in a research report on Friday. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price target for the company in a research report on Tuesday, August 1st. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. One research analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average target price of $189.50.

The stock’s 50-day moving average price is $177.43 and its 200 day moving average price is $168.86. The company has a market capitalization of $72.57 billion, a price-to-earnings ratio of 32.41 and a beta of 1.05.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the previous year, the business earned $2.03 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. Analysts forecast that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 11,318 shares of the business’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the sale, the director now directly owns 38,757 shares in the company, valued at $6,702,635.58. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director C Martin Harris sold 360 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares in the company, valued at $961,312.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,844 shares of company stock worth $3,300,421. 0.49% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of TMO. BlackRock Inc. raised its position in Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after acquiring an additional 22,165,530 shares in the last quarter. Capital Research Global Investors raised its position in Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after acquiring an additional 3,973,136 shares in the last quarter. Janus Henderson Group PLC raised its position in Thermo Fisher Scientific by 2,058.1% in the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after acquiring an additional 2,233,522 shares in the last quarter. C WorldWide Group Holding A S raised its position in Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock worth $299,527,000 after acquiring an additional 1,772,300 shares in the last quarter. Finally, Veritas Asset Management LLP raised its position in Thermo Fisher Scientific by 112.4% in the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after acquiring an additional 1,286,259 shares in the last quarter. Hedge funds and other institutional investors own 83.52% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Traders Sell Thermo Fisher Scientific Inc (TMO) on Strength (TMO)” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/05/traders-sell-thermo-fisher-scientific-inc-tmo-on-strength-tmo-4.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.